depression Archives -

On the latest instalment of the pharmaphorum podcast, editor in chief Jonah Comstock hosts Dr Benny Alouf, chief

Building a digital therapeutic for paediatric behavioural health – the pharmaphorum podcast

https://pharmaphorum.com/digital/building-a-digital-therapeutic-for-paediatric-behavioural-health/

News/ News/ R&D

Praxis wields the axe as lead depression drug fails

Phil Taylor Biogen, depression, Praxis Precision Medicines, Sage Therapeutics, zuranolone 0 Comment

Shares in Praxis Precision Medicines were in freefall today after the company’s efforts to develop a new therapy

Praxis wields the axe as lead depression drug fails

https://pharmaphorum.com/news/praxis-wields-the-axe-as-lead-depression-drug-fails/

News/ News/ R&D

AbbVie adds to Vraylar data as FDA considers depression use

Phil Taylor AbbVie, depression, Psychiatry, Vraylar 0 Comment

AbbVie has reported new phase 3 data for its schizophrenia and bipolar disorder therapy Vraylar in treatment-resistant depression,

AbbVie adds to Vraylar data as FDA considers depression use

https://pharmaphorum.com/news/abbvie-adds-to-vraylar-data-as-fda-considers-depression-use/

Digital/ News/ News/ News/ R&D

Beckley adds digital element to its psychedelic drug trials

Phil Taylor Beckley Psytech, depression, digital, digital health, patient monitoring, psychedelics, wearable 0 Comment

Phase 2 trials of Beckley Psytech’s psychedelic drug candidates will make use of digital technologies for patient monitoring,

Beckley adds digital element to its psychedelic drug trials

https://pharmaphorum.com/news/beckley-adds-digital-element-to-its-psychedelic-drug-trials/

News/ News/ R&D

AbbVie adds to neuroscience pipeline with $1bn Syndesi buy

Phil Taylor AbbVie, Alzheimer's disease, depression, M&A, neurology, Syndesi Therapeutics 0 Comment

Four years after spinning out from Belgium’s UCB, Syndesi Therapeutics and its SV2A modulator programme has been bought

AbbVie adds to neuroscience pipeline with $1bn Syndesi buy

https://pharmaphorum.com/news/abbvie-adds-to-neuroscience-pipeline-with-1bn-syndesi-buy/

Market Access/ News/ News

AbbVie files Vraylar as add-on therapy for depression in US

Phil Taylor AbbVie, depression, Psychiatry, regulatory, Vraylar 0 Comment

AbbVie has filed with the FDA to extend the uses of its bipolar disorder therapy Vraylar to include

AbbVie files Vraylar as add-on therapy for depression in US

https://pharmaphorum.com/news/abbvie-files-vraylar-as-add-on-therapy-for-depression-in-us/

News/ News/ R&D

Sage, Biogen’s zuranolone looks approvable, but will it sell?

Phil Taylor Biogen, depression, Psychiatry, Sage Therapeutics, zuranolone 0 Comment

Last year, the first phase 3 trial of Sage Therapeutics and Biogen’s antidepressant hopeful zuranolone hit its efficacy

Sage, Biogen’s zuranolone looks approvable, but will it sell?

https://pharmaphorum.com/news/sage-biogens-zuranolone-looks-approvable-but-will-it-sell/

Digital/ News/ News

Blue Note leukaemia DTx gets FDA breakthrough tag

Phil Taylor acute myeloid leukaemia, anxiety, Blue Note Therapeutics, depression, digital, digital health, Oncology 0 Comment

A prescription digital therapeutic (DTx) for leukaemia patients developed by Blue Note Therapeutics has been awarded breakthrough device

Blue Note leukaemia DTx gets FDA breakthrough tag

https://pharmaphorum.com/news/blue-note-leukaemia-dtx-gets-fda-breakthrough-tag/

News/ News/ R&D

Compass points to positive psilocybin trial, but shares fall

Phil Taylor Compass Pathways, depression, psychedelics, Psychiatry 0 Comment

Compass Pathways has reported that its drug for treatment-resistant depression (TRD) based on magic mushroom ingredient psilocybin was

Compass points to positive psilocybin trial, but shares fall

https://pharmaphorum.com/news/compass-points-to-positive-psilocybin-trial-but-shares-fall/

Trending

depression

Login